Coherus BioSciences (NASDAQ:CHRS – Free Report) had its price objective trimmed by Robert W. Baird from $11.00 to $9.00 in a research note issued to investors on Tuesday morning, Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock. Other equities research analysts have also issued research reports about the company. […]
By David Sachs Sandoz said that it will buy vision-impairment drug Cimerli from Coherus BioSciences for $170 million. The Swiss pharmaceutical company said.